17 Jun Amphivena Announces Upcoming Oral Presentation at AACR Virtual Annual Meeting II
South San Francisco, CA – June 17, 2020 — Amphivena Therapeutics, a clinical-stage immuno-oncology company focused on developing immuno-therapeutics that restore anti-cancer immunity, today announced that it will present translational data for its lead clinical candidate, AMV564, a bivalent T-cell engager, at the American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting II being held June 22 – 24.
The oral presentation (#5699) entitled, “AMV564, a bivalent, bispecific T-cell engager, depletes myeloid-derived suppressor cells and activates T cells in cancer patients” will be presented by the Company’s chief scientific officer, Victoria Smith, Ph.D..
Details of the Presentation:
- Session Title: Novel Immunotherapies and Mechanisms
- Session Start Date/Time: Tuesday, June 23, 2020, 9:00 – 11:00 AM ET
- Abstract Number: 4630
About Amphivena Therapeutics, Inc.
Amphivena Therapeutics, Inc. is a privately held, clinical-stage, immuno-oncology company based in South San Francisco, CA that is developing a novel platform of dual-action biologics to selectively relieve immune suppression and drive T-cell activation/polarization, to restore anti-cancer immunity in patients. The company’s lead therapeutic candidate, AMV564, induces selective T-cell mediated killing of myeloid derived suppressor cells (MDSC), known to be associated with immune suppression and poor outcomes to immunotherapy. In parallel, it drives T cell activation. AMV564 has exhibited an excellent clinical safety profile and combinability with checkpoint inhibition and represents a unique opportunity to bring new treatment options to cancer patients underserved by immunotherapy.
Amphivena has raised $88.5 M to date in Series A, B and C venture financings led by NanoDimension, Qiming Venture Partners USA, MPM Capital and funds managed by Tekla Capital Management LLC.
Alicia Chung, Corporate Development